O
Olli Kallioniemi
Researcher at University of Helsinki
Publications - 376
Citations - 44711
Olli Kallioniemi is an academic researcher from University of Helsinki. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 90, co-authored 353 publications receiving 42021 citations. Previous affiliations of Olli Kallioniemi include European Bioinformatics Institute & Åbo Akademi University.
Papers
More filters
Journal ArticleDOI
HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation
Saija Haapa-Paananen,Kiviluoto S,Marika Waltari,Marjut Puputti,J P Mpindi,J P Mpindi,Pekka Kohonen,Olli Tynninen,Hannu Haapasalo,Heikki Joensuu,Merja Perälä,Olli Kallioniemi,Olli Kallioniemi +12 more
TL;DR: HES6 is important for glioma cell proliferation and migration, and may have a role in angiogenesis, and a large-scale transcriptomics study of tissue samples from the GeneSapiens database concludes.
Journal ArticleDOI
Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
Ulla-Maija Haltia,Noora Andersson,Bhagwan Yadav,Anniina Färkkilä,Evgeny Kulesskiy,Matti Kankainen,Jing Tang,Ralf Bützow,Annika Riska,Arto Leminen,Markku Heikinheimo,Markku Heikinheimo,Olli Kallioniemi,Leila Unkila-Kallio,Krister Wennerberg,Tero Aittokallio,Tero Aittokallio,Mikko Anttonen +17 more
TL;DR: The selective synergy found between taxanes and dasatinib or mTOR inhibitors warrants further clinical investigations of these combinations in relapsed or aggressive AGCTs and demonstrates that high-throughput drug screening and molecular profiling can provide an effective approach to uncover new therapy options.
Journal ArticleDOI
Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.
Paula Vainio,Maija Wolf,Maija Wolf,Henrik Edgren,Tao He,Pekka Kohonen,Pekka Kohonen,John Patrick Mpindi,Frank Smit,Gerald W. Verhaegh,Jack A. Schalken,Merja Perälä,Kristiina Iljin,Kristiina Iljin,Olli Kallioniemi,Olli Kallioniemi,Olli Kallioniemi +16 more
TL;DR: Castration‐resistant prostate cancer (CRPC) represents a therapeutic challenge for current medications and should be considered as a clinical priority for new drug development.
Journal ArticleDOI
Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells
TL;DR: The results reveal that disulfiram alone does not block tumor growth in vivo nor induce apoptosis in vitro, indicating that combinatorial approaches may be required to enhance the anti-neoplastic effects, and propose novel combinatorially approaches to inhibit prostate cancer cell growth.
Journal ArticleDOI
ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.
Teijo Pellinen,Teijo Pellinen,Sami Blom,Sara Sanchez,Katja Välimäki,John Patrick Mpindi,Hind Azegrouz,Raffaele Strippoli,Raquel Nieto,Mariano Vitón,Irene Palacios,Riku Turkki,Yinhai Wang,Yinhai Wang,Miguel Sánchez-Álvarez,Stig Nordling,Anna Bützow,Tuomas Mirtti,Antti Rannikko,María C. Montoya,Olli Kallioniemi,Olli Kallioniemi,Miguel A. del Pozo +22 more
TL;DR: This work suggests TGFβ signalling and beta1 integrins as potential therapeutic targets in PCa over-expressing CAV1, and contributes to better understand the paradoxical dual role of TGF β in tumour biology.